Horm Metab Res 1984; 16(12): 658-662
DOI: 10.1055/s-2007-1014876
Clinical

© Georg Thieme Verlag, Stuttgart · New York

Catecholamines and Pituitary Function.

2. Prolactin Response to Different Dopamine Doses in Normal Cycling Women and Patients with Prolactin-Secreting Pituitary Tumors, both before and after Endogenous Catecholamine Synthesis InhibitionI. Nicoletti, P. Filipponi, L. Fedeli2 , G. Gregorini, F. Ambrosi, M. Sfrappini, F. Santeusanio1 , P. Brunetti1
  • Istitut di Clinica Medica, Universitá di Perugia, Perugia, Italy
  • 1Istitut di Patologia Medica, Universitá di Perugia, Perugia, Italy
  • 2Servizio di Medicina Nucleare del Policlinico, Perugia, Italy
Weitere Informationen

Publikationsverlauf

1983

1983

Publikationsdatum:
14. März 2008 (online)

Summary

The inhibitory effect of various doses of dopamine on serum PRL levels was assessed in both normal cycling women and patients with tumoral hyperprolactinemia before and after endogenous catecholamine synthesis inhibition by α-methyl-p-tyrosine, a strong and specific tyrosine-hydroxylase inhibitor.

Dopamine infusion induced a significant decrease in the serum PRL levels in both normal cycling and hyperprolactinemic subjects. The mean percent inhibition of baseline PRL induced by the various dopamine infusion rates (0.1, 0.5, 1.0 and 2.0 μg/kg/min) was similar in regularly cycling women and in patients with tumoral hyperprolactinemia both before and after endogenous catecholamine synthesis inhibition by α-methyl-p-tyrosine.

Alpha-methyl-p-tyrosine pretreatment significantly increased serum PRL concentrations in normal women and enhanced their responsiveness to the exogenously administered dopamine. Hyperprolactinemic patients, on the contrary, did not show any significant variation in either basal PRL release or the PRL sensitivity to dopamine infusion after endogenous catecholamine synthesis inhibition.

These data indicate that reduced dopamine delivery to the adenomatous lactotroph, either due to a primary hypothalamic abnormality or to a deranged vascular pituitary arrangement, rather than a reduced PRL sensitivity to dopamine inhibition, is the main event accounting for PRL hypersecretion in women with PRL-secreting pituitary tumors.

    >